Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech
Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech. The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402275595/en/
Biotech Award presented to Paul Bravetti (CEO Brenus Pharma) by Thierry Hulot (President of Merck Group activities in France - President of LEEM), Alain Huriez (Chariman and Managing Partner, AdBio Partners), Guillaume LAULHE (Director BD at IQVIA) (Photo: Brenus Pharma)
The jury, made up of over 70 scientific, institutional, political, industrial, and financial experts, awarded companies in the French Health-Tech industry that stood out for their creativity, imagination, and dynamism over the past two years. This is a great recognition from the French health ecosystem. (France Biotech Press Release)
This award testifies to the relevance of Brenus Pharma's mission: to restore the ability of cancer patients to fight resistant tumor cells and avoid relapses like never before. (Recording pitch)
"On behalf of the whole team, we thank all the jury members for this great distinction, as well as France Biotech for organizing this ceremony and for their crucial role as coordinator of the French health innovation ecosystem. Finally, congratulations to all the winning startups, nominees, and others who thrive and provide daily efforts for the health of patients." declares Paul BRAVETTI, CEO of Brenus Pharma.
About Brenus Pharma :
Brenus Pharma develops first-in-class proteomic-driven cell immunotherapies focused on tumor antigens for the treatment of solid tumors. Brenus has developed the STC platform (Stimulated Tumor Cells), a technological platform that mimics relapse conditions and allows the education of the patient's immune system to fight the resistance mechanisms of tumor cells.
https://www.brenus-pharma.com/ | Linkedin
About France Biotech
France Biotech, founded in 1997, is an independent association that brings together innovation entrepreneurs in healthcare and their expert partners. As a facilitator of the healthcare innovation ecosystem and a privileged interlocutor with public authorities in France and Europe, France Biotech contributes to addressing the challenges of the HealthTech sector (company financing, innovation taxation, regulatory issues, and market access, etc.) and proposing concrete solutions in terms of competitiveness and attractiveness through its committees and working groups. This is to help start-ups and SMEs in this sector to become successful international companies capable of quickly designing and developing new innovations and ultimately making them accessible to patients. France Biotech is housed at the PariSanté Campus. http://www.france-biotech.fr/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402275595/en/
Contact information
Press contact: Florence Portejoie - FP2COM | fportejoie@fp2com.fr | (+33) 06 07 76 82 83
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AWS and HUMAIN Expand Partnership with NVIDIA AI Infrastructure and AWS AI Chip Deal to Drive Global AI Innovation19.11.2025 20:38:00 EET | Press release
Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and HUMAIN, a Public Investment Fund (PIF) company delivering global full-stack AI solutions, announced today at the U.S.-Saudi Investment Forum their plans to provide, deploy and manage up to 150,000 AI accelerators in a data center facility known as an “AI Zone” in Riyadh. As part of the expanded partnership, AWS will become HUMAIN’s preferred AI partner globally, and the two companies will collaborate to bring AI compute and services from Saudi Arabia to customers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119637708/en/ Tanuja Randery, Managing Director, Europe, Middle East & Africa, AWS and Tareq Amin, CEO of HUMAIN The first-of-a-kind AI Zone in Saudi Arabia will support cutting-edge AI training and inference workloads with access to the latest NVIDIA GB300 AI infrastructure and AWS’s Trainium AI chips. The infrastructure will
Luma AI Raises $900 Million Series C Led by HUMAIN And Partners on 2 Gigawatt AI Supercluster in Saudi Arabia19.11.2025 19:15:00 EET | Press release
Luma AI, the frontier artificial intelligence company building multimodal AGI, today announced it has raised $900 million in Series C funding, led by HUMAIN, a PIF company delivering global full-stack AI solutions, with significant participation from AMD Ventures, and existing investors Andreessen Horowitz, Amplify Partners, and Matrix Partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119678010/en/ (L–R) Amit Jain, CEO of Luma AI, and Tareq Amin, CEO of HUMAIN, at the U.S.–Saudi Investment Forum in Washington, D.C., where Luma AI announced its $900 million Series C and partnership on Project Halo - a 2-gigawatt AI supercluster in Saudi Arabia that will power next-generation World Models and accelerate the path toward Multimodal AGI. This Series C is a milestone in the company’s mission to build multimodal general intelligence: AI that can generate, understand, and operate in the physical world. To train and deploy
Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement19.11.2025 17:00:00 EET | Press release
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, today announced that it has raised $5 million in seed funding. The round was led by Elevation Capital with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and several strategic angels from the global healthcare and AI ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119509940/en/ Rajashekar Vasantha (left), Supreet Deshpande (center), and Sahitya Sridhar (right), the founding team behind Synthio Labs’ voice-powered AI platform for pharma “We believe Synthio Labs is defining the next major Customer Engagement infrastructure for Life Sciences. Their Clinical-grade Voice AI platform unifies how pharma communicates - giving field teams a powerful voice companion, and giving physicians and patients instant, trusted, compliant answers 24/7. Pharma’s global Commercial and GTM foo
Torq Crushes EMEA Estimates With Record-Breaking Q3, Hitting 185% of Quarterly Target19.11.2025 16:00:00 EET | Press release
Torq, the autonomous security operations leader, today announced it has exceeded Q3 EMEA revenue estimates, achieving 185% of its quarterly target. Torq is now firmly established as EMEA’s autonomous security operations platform of choice as enterprise goliaths continue joining its customer ranks, including Virgin Atlantic, Kyocera, Siemens, and Zara. Torq’s EMEA headcount grew 400% across 2025 to accommodate the exponentially increasing demand. “As worldwide momentum accelerates, Torq is doubling down on its EMEA investment by expanding operations, growing regional leadership, and strengthening our on-the-ground presence to fuel our next stage of growth,” said Ofer Smadari, CEO and co-founder, Torq. “Torq is now trusted by many of the world’s largest brands inside some of the most complex and sophisticated security operations centers. With new expansion into Germany, Hungary, Poland, Slovenia, and Switzerland, we are continuing to scale our footprint across the region. EMEA’s most suc
Xsolla Releases “The Xsolla Report: State of Play Q3 2025 Edition, Vol. 8,” Delivering Clear, Data-Led Insights for Game Developers19.11.2025 16:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their products, today announces the release of The Xsolla Report: State of Play Q3 2025 Edition, Vol. 8, a comprehensive analysis of market forces shaping the games industry. The report synthesizes the latest data and expert perspectives to help developers and publishers plan for sustainable growth across platforms and regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119397781/en/ Graphic: Xsolla As developers navigate new distribution models and evolving monetization approaches, the Q3 2025 edition offers a practical perspective on where the market is heading. The global player base is projected to reach 3.6 billion by year-end, with revenue on track to reach $188.8 billion—driven by steady momentum, including console hardware refreshes, PC gains in Asia, and ongoing strength in mobile. Key highlights from the Q3 2025 edi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom